Xenon Pharmaceuticals (XENE) Institutional Ownership
13F filers reported holding 51.1% of Xenon Pharmaceuticals (XENE) shares as of Sep 30, 2026, across 197 filers.
- Held by 13F filers
- 51.1%
- Sep 30, 2026
- 13F filers
- 197
- quarter ended Sep 30, 2026
- 13F value
- $1.9B
- 50.2M shares
- Quarter's fund flow
- Mild accumulation
- 23 new · 30 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | Kelly Thomas Patrick | Chief Financial Officer | Acquired · Option exercise | 7,500Common Shares | — | ↗ |
| Oct 15, 2026 | Kelly Thomas Patrick | Chief Financial Officer | Disposed · Option exercise | 7,500Restricted Share Units | — | ↗ |
| Sep 30, 2026 | Kelly Thomas Patrick | Chief Financial Officer | Acquired · Open-market buy | 15,000Common Shares | $37.32 | ↗ |
| Sep 30, 2026 | MORTIMER IAN | PRESIDENT & CEO | Acquired · Open-market buy | 30,000Common Shares | $37.38 | ↗ |
| Sep 1, 2026 | Svoronos Dawn | director | Acquired · Option exercise | 5,144Common Shares | $8.15 | ↗ |
| Sep 1, 2026 | Svoronos Dawn | director | Disposed · Option exercise | 5,144Stock Option (Right to Buy) | — | ↗ |
| Aug 28, 2026 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Disposed · Open-market sale | 6,368Common Shares | $60.17 | ↗ |
| Aug 28, 2026 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Disposed · Open-market sale | 700Common Shares | $60.98 | ↗ |
| Aug 11, 2026 | GANNON STEVEN | director | Disposed · Open-market sale | 10,000Common Shares | $64.06 | ↗ |
| Jun 5, 2026 | PATOU GARY | director | Disposed · Open-market sale | 1,322Common Shares | $53.14 | ↗ |
| Jun 5, 2026 | Cannon Gillian | director | Disposed · Open-market sale | 1,190Common Shares | $53.14 | ↗ |
| Jun 3, 2026 | PATOU GARY | director | Acquired · Grant / award | 10,507Share Option (Right to Buy) | — | ↗ |
| Jun 3, 2026 | PATOU GARY | director | Acquired · Grant / award | 1,593Restricted Share Units | — | ↗ |
| Jun 3, 2026 | Machado Patrick | director | Acquired · Grant / award | 10,507Share Option (Right to Buy) | — | ↗ |
| Jun 3, 2026 | Machado Patrick | director | Acquired · Grant / award | 1,593Restricted Share Units | — | ↗ |
| Jun 3, 2026 | Gover Justin D. | director | Acquired · Grant / award | 10,507Share Option (Right to Buy) | — | ↗ |
| Jun 3, 2026 | Gover Justin D. | director | Acquired · Grant / award | 1,593Restricted Share Units | — | ↗ |
| Jun 3, 2026 | GAROFALO ELIZABETH A. | director | Acquired · Grant / award | 10,507Share Option (Right to Buy) | — | ↗ |
| Jun 3, 2026 | GAROFALO ELIZABETH A. | director | Acquired · Grant / award | 1,593Restricted Share Units | — | ↗ |
| Jun 3, 2026 | GANNON STEVEN | director | Acquired · Grant / award | 10,507Share Option (Right to Buy) | — | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Xenon Pharmaceuticals do institutions hold?
13F filers reported holding 51.1% of Xenon Pharmaceuticals' shares as of Sep 30, 2026, across 197 filers.
How many 13F filers hold Xenon Pharmaceuticals?
Xenon Pharmaceuticals was held by 197 13F filers as of Sep 30, 2026.
Not investment advice.

